{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-26-000079","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2026-09-08T11:05:26+00:00","discovered_at":"2026-09-08T11:10:00.253664+00:00","generated_at":"2026-09-08T11:10:16.289258+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kiora appoints Keith Lane as EVP of Clinical Development and Regulatory Affairs","bullets":["Lane appointed EVP, Head of Clinical Development and Regulatory Affairs effective Sept 8, 2026.","Compensation: $350k base salary, $75k sign-on bonus, 35% base target bonus, 55k share option grant.","Lane brings 20+ yrs ophthalmic experience from Ora; oversaw 60+ trials, incl. 12 global Phase 3 studies.","Will lead U.S./global clinical development for KIO-301 (retinitis pigmentosa) and other pipeline assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-26-000079","json":"https://secwatch.observer/filing/0001372514-26-000079.json","markdown":"https://secwatch.observer/filing/0001372514-26-000079.md","text":"https://secwatch.observer/filing/0001372514-26-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/0001372514-26-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/kprx-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:10:16.289258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}